RMWC Unlimited Innovation Pty Ltd

About RMW Cho Group
RMW Cho Group is the licensor and owner of the Photosoft™ Technology, which was developed by the Company’s founder Michael Cho. Michael invested over 20 years developing Photosoft as the Next Generation Photodynamic Therapy, and preclinical studies have shown the technology to be a promising new treatment modality for a range of cancers and other diseases. Photosoft is covered by a number of patent families including major markets and Australia. RMW is currently working closely with Invion to undertake first-in-human clinical trials on cancers in Australia. With strong safety and efficacy results, Photosoft has the potential to change the revolutionise the way insidious diseases are treated globally.

About Invion Limited
Invion is a clinical stage life-science company listed on the Australian Securities Exchange (ASX: IVX) that is leading the global research and development of the Photosoft™ Technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The Company is close to commencing clinical trials in cancer indications and is working with preeminent Australian research partners like the Peter MacCallum Cancer Centre and Hudson Institute of Medical Research, and leading South Korean pharma group, Hanlim Pharma Co., Ltd.

Results to date show Photosoft has the potential to regress multiple cancer types, impede metastatic cancers and stimulate the body’s immune response. Photosoft has also demonstrated effectiveness against bacteria, fungi and viruses, including MRSA, COVID-19 and dengue in vitro.

Invion, which is on track to achieve multiple key development milestones over the next year or two, holds the exclusive rights to Photosoft for most of Asia Pacific (APAC) for cancers, atherosclerosis and infectious diseases, plus the US and Canadian rights for Infectious diseases indications.

View Site Show On Map